- Home
- RGLS vs ABP Comparison
RGLS vs ABP Comparison
Compare RGLS & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLS
- ABP
- Stock Information
- Founded
- RGLS 2007
- ABP 2004
- Country
- RGLS United States
- ABP United States
- Employees
- RGLS N/A
- ABP N/A
- Industry
- RGLS Biotechnology: Pharmaceutical Preparations
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- RGLS Health Care
- ABP Health Care
- Exchange
- RGLS Nasdaq
- ABP Nasdaq
- Market Cap
- RGLS 74.0M
- ABP 76.2M
- IPO Year
- RGLS 2012
- ABP N/A
- Fundamental
- Price
- RGLS $1.31
- ABP $0.84
- Analyst Decision
- RGLS Strong Buy
- ABP
- Analyst Count
- RGLS 6
- ABP 0
- Target Price
- RGLS $10.33
- ABP N/A
- AVG Volume (30 Days)
- RGLS 820.1K
- ABP 39.1K
- Earning Date
- RGLS 03-20-2025
- ABP 03-07-2025
- Dividend Yield
- RGLS N/A
- ABP N/A
- EPS Growth
- RGLS N/A
- ABP N/A
- EPS
- RGLS N/A
- ABP N/A
- Revenue
- RGLS N/A
- ABP $230,000.00
- Revenue This Year
- RGLS N/A
- ABP N/A
- Revenue Next Year
- RGLS N/A
- ABP N/A
- P/E Ratio
- RGLS N/A
- ABP N/A
- Revenue Growth
- RGLS N/A
- ABP N/A
- 52 Week Low
- RGLS $0.83
- ABP $0.80
- 52 Week High
- RGLS $3.79
- ABP $13.00
- Technical
- Relative Strength Index (RSI)
- RGLS 53.78
- ABP N/A
- Support Level
- RGLS $1.22
- ABP N/A
- Resistance Level
- RGLS $1.60
- ABP N/A
- Average True Range (ATR)
- RGLS 0.13
- ABP 0.00
- MACD
- RGLS 0.03
- ABP 0.00
- Stochastic Oscillator
- RGLS 50.85
- ABP 0.00
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.